NAGENiagen Bioscience Inc. Common Stock

In early August 2026, Niagen Bioscience Inc. reported slightly lower quarterly sales and net income year on year, while also expanding access to its Tru Niagen® healthy‑aging NAD+ supplement via Walmart.com, initially offering 300 mg bottles in 30‑ and 90‑count formats. A new peer‑reviewed analysis in Aging Cell linked Niagen’s nicotinamide riboside supplementation to reduced muscle epigenetic age acceleration, adding scientific depth to its healthy‑aging positioning just as distribution...

Niagen Bioscience (NAGE) is back in focus after a new peer reviewed study reported that its Niagen nicotinamide riboside supplementation was associated with reduced muscle epigenetic age acceleration compared with exercise based protocols. See our latest analysis for Niagen Bioscience. The recent clinical findings arrive after a difficult stretch for Niagen Bioscience’s stock. The 1 day share price return has fallen 14.7% and the year to date share price return has declined 52.64%. However,...

Niagen Bioscience Inc (NAGE) reports strong TrueNiagen sales growth, China cross-border revenue exceeding full-year 2025 totals, and advances in pharmaceutical pipeline with promising PRV potential.

Niagen Bioscience (NAGE) delivered earnings and revenue surprises of 0.00% and -0.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?